SCHEMBL31742425

SCHEMBL31742425

O=c1oc(-c2ccc(Br)cc2)nc2cc([N+](=O)[O-])ccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.64
KMT2A Q03164 6/20 0.64
MAPT P10636 6/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
RAB9A P51151 8/20 0.62
TDP1 Q9NUW8 1/20 0.62
F7 P08709 1/20 0.61
F3 P13726 1/20 0.61
C1R P00736 3/20 0.60
NPC1 O15118 7/20 0.59
RXFP1 Q9HBX9 1/20 0.59
ELANE P08246 1/20 0.57
MCL1 Q07820 1/20 0.53
ATM Q13315 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
POLB P06746 1/20 0.52
ALDH1A1 P00352 2/20 0.50
GABRP O00591 1/20 0.49
GABRD O14764 1/20 0.49
GABRA1 P14867 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6567235 0.93 MEN1 (0.72) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL31742426 0.88 RAB9A (0.75) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL11812017 0.87 MAPT (0.76) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL6170277 0.84 MEN1 (0.60) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL157666 0.83 MEN1 (0.81) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL4146732 0.83 RAB9A (0.76) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL31742429 0.82 MAPT (0.65) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL6563905 0.82 RAB9A (0.78) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL914201 0.82 MEN1 (0.68) MEN1KMT2AMAPTL3MBTL1RAB9A
SCHEMBL4153246 0.80 RAB9A (0.75) MEN1KMT2AMAPTL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250375454-A1 METHODS FOR TREATING HEPATOCELLULAR CARCINOMA UNIV HONG KONG POLYTECHNIC 2025-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375454-A1 METHODS FOR TREATING HEPATOCELLULAR CARCINOMA MYC, BCL2, MYCBP MEN1 4101/4885KMT2A 2400/4885MAPT 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.